Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Recent Releases: Polio Eradication; Chagas Disease Discovery Anniversary; River Blindness; Malaria Tools; Childhood Malnutrition
MMWR Examines Polio Eradication In India
generic viagra online
Blogs Comment On Need For Abortion Providers, Antiabortion-Rights Protests, Other Topics
The following summarizes selected women"s health-related blog entries. ~ "Obama"s True Colors: Appointee Opposes Abortion and Birth Control," Bonnie Erbe, U.S. News & World Report"s "Thomas Jefferson Street": President Obama"s appointment of Alexia Kelley, founder of Catholics in Alliance for the Common Good, as director of the Office of Faith-Based and Community Partnerships at HHS "doesn"t surprise me at all," Erbe writes, adding that Obama is "merely feeling comfortable enough to show his true self, rather than staying true to promises he made to his supporters prior to being elected." Erbe includes an excerpt from Frances Kissling"s Salon opinion piece in which Kissling questions whether Kelley will follow through with the Obama administration"s pledges to implement policies that help prevent teenage pregnancy and reduce the need for abortion. Erbe concludes, "[A]s the evidence mounts that winning re-election is more important to this president than anything else, his supporters should re-examine their votes in 2012" (Erbe, "Thomas Jefferson Street," U.S. News & World Report, 6/8).~ "This Weekend is the International Demonstration Against Birth Control," Cristina Page, Birth Control Watch: "This weekend marks the second year of "The Pill Kills" campaign," which its antiabortion-rights organizers are calling the ""International Demonstration Against Birth Control"" that they say will ""expose the tragic effects"" hormonal contraception has on women, Page writes. She writes that while last year"s campaign focused on convincing women that birth control pills and other common contraceptives "were really abortion methods," this year"s campaign "is trying to scare women" from using birth control "by claiming it will kill them." The campaign "targets the regular birth control pill in particular," Page says, adding that "it appears impossible to find a single instance in which any pro-life group has anything good to say about any birth control method except natural family planning -- a technique most notable for its high failure rate." She notes, "Even the lowly condom disturbs them." According to Page, David Grimes, "one of the world"s leading experts on contraception," said that ""some antiabortion groups describe a subtle blend of fake claims and real, but exaggerated, risks to frighten women,"" and only ""those very knowledgeable can tease out which are which."" Grimes also noted, ""Ironically, the net effect of this campaign to discredit contraception is more unplanned pregnancies and, of course, more abortions."" Page writes, "One can safely say" that the American Life League -- lead organizer of "The Pill Kills" campaign -- has a "desire to ban birth control [that] is equally intense as its campaign against legal abortion." As evidence of this, she cites the group"s efforts to defeat legislation offering contraception coverage for federal employees and its distribution of anti-contraception literature. She adds, "Not only does ALL promote" that "birth control is abortion," but it "also put[s] forth that any attempt to prevent pregnancy during sex is tantamount to having an abortion." Page concludes, "In actuality," efforts by ALL and similar groups "punish people for having the type of sex they define as contrary to God"s wishes. Pregnancy is, according to them, what sex is for" (Page, "Birth Control Watch," 6/5).~ "The Next Generation of Providers: One Doctor Shows the Way," Sheila Bapat, RH Reality Check: The recent murder of Kansas abortion provider George Tiller "brings into sharp relief the gravity" of women"s health care providers" decision to perform abortions, Bapat writes. She profiles an ob-gyn -- a "young woman in her early 30s" -- who holds a faculty position at a university hospital in a southern, conservative state and also is "one of just a handful of abortion providers in the South." Bapat writes that the "low number of abortion providers" in the U.S. is the result of several factors, including fear o
News of the day
Nineteen House Dems Plan To Vote Against Health Reform If Abortion Funding Is Included
Nineteen House Democrats recently sent a letter to House Speaker Nancy Pelosi (D-Calif.) stating that they will not vote for health care reform legislation "unless it explicitly excludes abortion funding from the scope of any government-defined or subsidized health insurance plan," CongressDaily reports. In the letter, the lawmakers wrote that they want to ensure that the Health Benefits Advisory Committee cannot recommend that abortion services be included as part of benefits packages. They wrote, "Without an explicit exclusion, abortion could be included in a government-subsidized health care plan under general health care." The letter was signed by Reps. Dan Boren (Okla.), Bobby Bright (Ala.), Travis Childers (Miss.), Jerry Costello (Ill.), Lincoln Davis (Tenn.), Kathleen Dahlkemper (Pa.), Steve Driehaus (Ohio), Tim Holden (Pa.), Paul Kanjorski (Pa.), Marcy Kaptur (Ohio), Mike McIntyre (N.C.), Charlie Melancon (La.), John Murtha (Pa.), James Oberstar (Minn.), Solomon Ortiz (Texas), Collin Peterson (Minn.), Heath Shuler (N.C.), Bart Stupak (Mich.) and Gene Taylor (Miss.) (CongressDaily, 6/30).
Sexual Health

ZymoGenetics Reports Encouraging Preliminary Results From Phase 2 Study Of IL-21 In Metastatic Melanoma Conducted By NCIC

ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that Interleukin 21 (IL-21) demonstrated an impressive overall response rate in the treatment of metastatic melanoma. In interim Phase 2 results from 24 patients, 29 percent showed a partial response, with an additional 33 percent of patients showing stable disease in this difficult to treat disease. "We are seeing promising anti-tumor response with IL-21 in patients with metastatic melanoma in this Phase 2 study," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics. "The response rate is favorable, particularly when compared to those of approved agents. Patients with advanced melanoma have few effective treatment options, so a clear need exists for new agents to manage this disease." Results from the Phase 2 clinical trial in patients with metastatic melanoma were presented at the World Congress on Melanoma meeting in Vienna, Austria. The single-agent multi-center clinical trial is being conducted by the NCIC Clinical Trials Group in Canada and is evaluating three dosing regimens of IL-21 in patients with no prior systemic therapy for metastatic melanoma. The primary endpoint is efficacy, as measured by objective response or lack of early disease progression. To date 7 of the 24 patients (29%) had a partial response (5 confirmed by RECIST criteria). Eight patients (33%) had stable disease. The most common adverse events were mild or moderate fatigue and rash. Two schedules testing 50 mcg/kg were evaluated in a total of 10 patients but were poorly tolerated due to adverse events including neutropenia and skin rash. The trial will be completed with a full cohort of 30 patients to be treated at the 30 mcg/kg dose, which is tolerable for outpatient dosing and active as assessed by tumor response. About Interleukin 21 (IL-21) IL-21, a cytokine that enhances CD8+ T cell and NK cell activity, has single-agent anti-tumor activity (J Clin Oncol 26:2034, 2008). ZymoGenetics has worldwide rights to IL-21 and is developing IL-21 for the treatment of renal cell carcinoma and metastatic melanoma. ZymoGenetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009